Abstract:Introduction 11 C-labeled Pittsburgh compound B ( 11 C-PiB) PET imaging can provide information for the diagnosis of Alzheimer's disease (AD) by quantifying the binding of PiB to β-amyloid deposition in the brain. Quantification index, such as standardized uptake value ratio (SUVR) and distribution volume ratio (DVR), has been exploited to effectively distinguish between healthy and subjects with AD. However, these measures require a long wait/scan time, as well as the selection of an optimal reference region. In this study, we propose an alternate measure named amyloid quantification index (AQI), which can be obtained with the first 30-min scan without the selection of the reference region. Methods 11 C-labeled Pittsburgh compound B PET scan data were obtained from the public dataset “OASIS-3”. A total of 60 mild subjects with AD and 60 healthy controls were included, with 50 used for training and 10 used for testing in each group. The proposed measure AQI combines information of clearance rate and mid-phase PIB retention in featured brain regions from the first 30-min scan. For each subject in the training set, AQI, SUVR, and DVR were calculated and used for classification by the logistic regression classifier. The receiver operating characteristic (ROC) analysis was performed to evaluate the performance of these measures. Accuracy, sensitivity, and specificity were reported. The Kruskal–Wallis test and effect size were also performed and evaluated for all measures. Then, the performance of three measures was further validated on the testing set using the same method. The correlations between these measures and clinical MMSE and CDR-SOB scores were analyzed. Results The Kruskal–Wallis test suggested that AQI, SUVR, and DVR can all differentiate between the healthy and subjects with mild AD ( p < 0.001). For the training set, ROC analysis showed that AQI achieved the best classification performance with an accuracy rate of 0.93, higher than 0.88 for SUVR and 0.89 for DVR. The effect size of AQI, SUVR, and DVR were 2.35, 2.12, and 2.06, respectively, indicating that AQI was the most effective among these measures. For the testing set, all three measures achieved less superior performance, while AQI still performed the best with the highest accuracy of 0.85. Some false-negative cases with below-threshold SUVR and DVR values were correctly identified using AQI. All three measures showed significant and comparable correlations with clinical scores ( p < 0.01). Conclusion Amyloid quantification index combines early-phase kinetic information and a certain degree of β-amyloid deposition, and can provide a better differentiating performance using the data from the first 30-min dynamic scan. Moreover, it was shown that clinically indistinguishable AD cases regarding PiB retention potentially can be correctly identified.

High Contrast PET Imaging of Subcortical and Allocortical Amyloid-β in Early Alzheimer's Disease Using [11C]AZD2184

Visual Assessment Versus Quantitative Assessment of 11C-PIB PET and 18F-FDG PET for Detection of Alzheimer's Disease

Amyloid PET in Dementia Syndromes: A Chinese Multicenter Study

IC‐P‐011: Amyloid PET Imaging Using AZD4694 and Unusually Brief Radiotracer Uptake and Scanning Periods

Clinical, Neuropsychological, and Neuroimaging Characteristics of Amyloid- Positive Vs. Amyloid-negative Patients with Clinically Diagnosed Alzheimer’s Disease and Amnestic Mild Cognitive Impairment

P1‐155: Amyloid PET Imaging Using AZD4694 and Unusually Brief Radiotracer Uptake and Scanning Periods

The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact

P1‐408: 18F‐FDG AND 18F‐AV45 POSITRON EMISSION TOMOGRAPHY IN ALZHEIMER'S DISEASE

Using Positron Emission Tomography And Florbetapir F 18 To Image Cortical Amyloid In Patients With Mild Cognitive Impairment Or Dementia Due To Alzheimer Disease

11C-PIB PET and 18F-FDG PET in patients with Alzheimer's disease and amnestic mild cognitive impairment

Study Of Tau Deposition In Patients Of Alzheimer'S Disease With [F-18]-Apn-1607 Pet Tracer And Its Relationship With Cerebral Glucose Metabolism

Screening of [18f]florbetazine for Aβ Plaques and a Head-to-Head Comparison Study with [11c]pittsburgh Compound-B ([11c]pib) in Human Subjects

F - FDG PET in Patients with Alzheimer's Disease and Amnestic Mild Cognitive Impairment ·neuroimaging Study of Alzheimer's Disease·

Identifying Mild Alzheimer's Disease With First 30-Min 11C-PiB PET Scan

Amyloid PET detects the deposition of brain Aβ earlier than CSF fluid biomarkers

Evaluating [68Ga]ga-P14-032 As a Novel PET Tracer for Diagnosis Cerebral Amyloid Angiopathy

Multimodal analysis using [11C]PiB-PET/MRI for functional evaluation of patients with Alzheimer's disease

The correlation between striatal and cortical binding ratio of 11C-PiB-PET in amyloid-uptake-positive patients

Statistical Parametric Mapping in Amyloid Positron Emission Tomography

The Image Quality, Amyloid-Β Detectability, and Acquisition Time of Clinical Florbetapir Positron Emission Tomography in Alzheimer's Disease and Healthy Adults.

Evaluation of a novel PET tracer [18F]-Florbetazine for Alzheimer's disease diagnosis and β-amyloid deposition quantification